First Use of Tapinarof Monotherapy for Seborrhoeic Dermatitis: A Case Report
DOI:
https://doi.org/10.2340/actadv.v103.12343Keywords:
Seborrheic Dermatitis, TapinarofAbstract
Abstract is missing (Short communication)
Downloads
References
Szepietowski JC, Reich A, Wesołowska-Szepietowska E, Baran E, Group NQoLiD. Quality of life in patients suffering from seborrheic dermatitis: influence of age, gender and education level. Mycoses 2009; 52: 357-363.
https://doi.org/10.1111/j.1439-0507.2008.01624.x DOI: https://doi.org/10.1111/j.1439-0507.2008.01624.x
Jackson JM, Alexis A, Zirwas M, Taylor S. Unmet needs for patients with seborrheic dermatitis. J Am Acad Dermatol 2022 Dec 17 [Online ahead of print].
https://doi.org/10.1016/j.jaad.2022.12.017 DOI: https://doi.org/10.1016/j.jaad.2022.12.017
Borda LJ, Wikramanayake TC. Seborrheic dermatitis and dandruff: a comprehensive review. J Clin Investig Dermatol 2015; 3: 10.13188/2373-1044.1000019.
https://doi.org/10.13188/2373-1044.1000019 DOI: https://doi.org/10.13188/2373-1044.1000019
Keam SJ. Tapinarof cream 1%: first approval. Drugs 2022; 82: 1221-1228.
https://doi.org/10.1007/s40265-022-01748-6 DOI: https://doi.org/10.1007/s40265-022-01748-6
Adalsteinsson JA, Kaushik S, Muzumdar S, Guttman-Yassky E, Ungar J. An update on the microbiology, immunology and genetics of seborrheic dermatitis. Exp Dermatol 2020; 29: 481-489.
https://doi.org/10.1111/exd.14091 DOI: https://doi.org/10.1111/exd.14091
Gary G. Optimizing treatment approaches in seborrheic dermatitis. J Clin Aesthet Dermatol 2013; 6: 44.
Kastarinen H, Okokon EO, Verbeek JH. Topical anti-inflammatory agents for seborrheic dermatitis of the face or scalp: summary of a Cochrane Review. JAMA Dermatol 2015; 151: 221-222.
https://doi.org/10.1001/jamadermatol.2014.3186 DOI: https://doi.org/10.1001/jamadermatol.2014.3186
Nogueira S, Rodrigues MA, Vender R, Torres T. Tapinarof for the treatment of psoriasis. Dermatol Ther 2022; 35: e15931.
https://doi.org/10.1111/dth.15931 DOI: https://doi.org/10.1111/dth.15931
Uppal SK, Chat VS, Kearns DG, Wu JJ. Topical agents currently in phase II or phase III trials for atopic dermatitis. J Drugs Dermatol 2020; 19: 956-959.
https://doi.org/10.36849/JDD.2020.5214 DOI: https://doi.org/10.36849/JDD.2020.5214
Smith SH, Jayawickreme C, Rickard DJ, Nicodeme E, Bui T, Simmons C, et al. Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans. J Invest Dermatol 2017; 137: 2110-2119.
https://doi.org/10.1016/j.jid.2017.05.004 DOI: https://doi.org/10.1016/j.jid.2017.05.004
Sutter CH, Azim S, Wang A, Bhuju J, Simpson AS, Uberoi A, et al. Ligand-activation of the aryl hydrocarbon receptor up-regulates epidermal UDP-glucose ceramide glucosyltransferase and glucosylceramides. J Invest Dermatol 2023 Mar 31 [online ahead of print].
https://doi.org/10.1016/j.jid.2023.03.1662 DOI: https://doi.org/10.1016/j.jid.2023.03.1662
Sekhon S, Koo J. Indirubin: a novel topical agent in the treatment of psoriasis. Br J Dermatol 2018; 178: 21-21.
https://doi.org/10.1111/bjd.16074 DOI: https://doi.org/10.1111/bjd.16074
Magiatis P, Pappas P, Gaitanis G, Mexia N, Melliou E, Galanou M, et al. Malassezia yeasts produce a collection of exceptionally potent activators of the Ah (dioxin) receptor detected in diseased human skin. J Invest Dermatol 2013; 133: 2023-2030.
https://doi.org/10.1038/jid.2013.92 DOI: https://doi.org/10.1038/jid.2013.92
Park HB, Goddard TN, Oh J, Patel J, Wei Z, Perez CE, et al. Bacterial autoimmune drug metabolism transforms an immunomodulator into structurally and functionally divergent antibiotics. Angewandte Chemie 2020; 132: 7945-7954.
https://doi.org/10.1002/ange.201916204 DOI: https://doi.org/10.1002/ange.201916204
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Naiem T. Issa, Michael Kaiser
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
